This CME/CE program will examine the evolving role of high-efficacy anti-CD40 therapeutics in relapsing multiple sclerosis (RMS), with a focus on how emerging treatments may address both acute and chronic neuroinflammation. Expert faculty, Dr. Fred Lublin, will first review evolving concepts in MS pathophysiology, including the role of CNS-compartmentalized inflammation, microglial activation, meningeal lymphoid follicles, and progression independent of relapse activity. Dr. Lublin will then explore the CD40/CD40L pathway, elucidating its role in innate and adaptive immune activation for patients with MS. To conclude, ongoing clinical trial data in RMS and non-relapsing secondary progressive MS, including IV and subcutaneous administration strategies, will be discussed and contextualized for current clinical implications.
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of CD40 in treatment planning
Develop treatment plans to delay disability and progression in patients with RMS
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Fred D. Lublin, MD | Consultant/Advisor: AbbVie Inc.; Amgen; Ardanza Biopharma; Autolus Limited; Avotres; Bristol Myers Squibb; Cognito Therapeutics; EMD Serono; Genentech, Inc.; Genzyme; ImmPACT Bio; Immunic Therapeutics; InnoCare Pharma; Kite Pharma; Neuralight; Novartis Pharmaceuticals Corporation; Roche AG; Sanofi; SetPoint Medical; Sudo Biosciences; Viatris Inc.; Zenas BioPharma
Grant/Research Support: Bristol Myers Squibb; Novartis Pharmaceuticals Corporation Speaker’s Bureau: Sanofi Stock Options: Avotres; Neuralight |
Timothy Hayes, MD, PhD; Joseph Feick, PharmD; Kim Cheramie, PhD, MSN, RN, NPDA-BC, Nicole McMenamin and Chelsey Simonds hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 0.50 AMA PRA Category 1 CreditsTM.
AcademicCME designates this enduring material for a maximum of 0.50 CNE Contact Hours, including 0.50 Pharmacotherapeutic Contact Hours (Provider #P0491).
AcademicCME designates this continuing education activity for 0.50 CPE Contact Hours (0.05 CEUs) of Continuing Pharmacy Education Credit (UAN # JA4008190-0000-26-017-H01-P).
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity is supported by an independent educational grant from Sanofi.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Sanofi do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
